<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   DFB Pharmaceuticals, Inc.
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        965516164
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       139062
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       3
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   DFB Pharmaceuticals contributes to drug development and manufacturing processes by providing essential ingredients. The company produces various pharmaceutical ingredients for its own use and for other drug makers through its Phyton Biotech operating subsidiary. Phyton Biotech uses its plant cell culture technology to make APIs (active pharmaceutical ingredients). Phyton Biotech is a global provider of chemotherapeutic agents including paclitaxel and docetaxel APIs and taxane intermediates. Affiliate Phyton LTD. operates Phyton Biotech LLC, and Phyton Biotech, GmbH.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Geographic Reach.flsnp" />
  <p>
   DFB Pharmaceuticals is based in Texas. Phyton Biotech has development and manufacturing facilities near Hamburg, Germany and in Vancouver, Canada.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Operations.flsnp" />
  <p>
   Phyton Biotech, which has produced taxanes for products such as anti-cancer drug Taxol (marketed by
   <company id="10232">
    Bristol-Myers Squibb
   </company>
   ), focuses on producing plant-cell-culture-based ingredients used in chemotherapy drugs. Phyton Biotech provides taxane, plant-cell fermentation, and protein development services to help drugmakers formulate new APIs; it also offers rapid scale-up manufacturing services of ingredients as products are developed and commercialized.
  </p>
  <p>
   The total production capacity of the taxanes train runs up to 880,000 liters per year. Phyton also offers development services to its customers via plant cell fermentation, chemical semi-synthesis, and purification for taxanes, secondary metabolites, recombinant proteins, and other active ingredients.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Sales and Marketing.flsnp" />
  <p>
   The company focuses on patient, payor, and provider needs in the wound care and surgical markets. Phyton Biotech markets its products to companies in the Biopharmaceuticals, Cosmeceuticals, Nutraceuticals, and Pharmaceuticals sectors.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Financial Performance.flsnp" />
  <p>
   The company gets about half of its revenues from marketed compounds or services as a result of acquisitions or partnerships.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Strategy.flsnp" />
  <p>
   DFB is growing its core businesses and expand its portfolio of products and technologies through dedicated research and development efforts and through strategic business partnerships. The company's services and solutions are focused primarily on semi-solid and liquid dosage forms. Phyton Biotech is focusing on bringing  a new generation of PCF-produced small molecules and protein therapeutics to the market.
  </p>
  <p>
   To generate cash and refocus its business, DFB sold a majority stake in its contract manufacturing unit
   <company id="139060">
    DPT Laboratories
   </company>
   to Renaissance Acquisition Holdings in 2012. Through the DPT transaction, DFB retained an interest in the DPT business and gained a seat on Renaissance's board.
  </p>
  <p>
   DFB also sold its
   <company id="139141">
    Healthpoint
   </company>
   subsidiary, a maker of prescription drugs to prevent or treat disorders associated with skin and soft tissue, to
   <company id="90390">
    Smith &amp; Nephew
   </company>
   for some $782 million. The unit had been facing a federal investigation into questionable marketing activities.
  </p>
 <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
